【摘要】：目的:觀察地爾硫卓聯(lián)合環(huán)孢素治療腎病綜合征伴急性腎損傷的療效和安全性。方法:66例腎病綜合征伴急性腎損傷患者隨機分為對照組(30例)和觀察組(36例)。對照組患者給予常規(guī)治療;觀察組患者在對照組治療的基礎(chǔ)上給予鹽酸地爾硫卓片15 mg,口服,每日2次,環(huán)孢素軟膠囊1.5 mg/(kg·d),口服,每日2次。兩組療程均為20 d。觀察兩組患者的臨床療效,治療前后血肌酐、腎損傷分子1(KIM_(-1))、24 h尿蛋白量、24 h尿量、急性腎損傷分級,隨訪及復(fù)發(fā)情況,并記錄不良反應(yīng)發(fā)生情況。結(jié)果:觀察組患者緩解率顯著高于對照組,復(fù)發(fā)率顯著低于對照組,差異均有統(tǒng)計學(xué)意義(P0.05)。治療前,兩組患者血肌酐、KIM_(-1)、24 h尿蛋白量、24 h尿量、急性腎損傷分級比較,差異均無統(tǒng)計學(xué)意義(P0.05)。觀察組患者治療2周、1個月后及對照組治療1個月后血肌酐、KIM_(-1)、24 h尿蛋白量均顯著低于同組治療前,且觀察組顯著低于對照組同期;24 h尿量、急性腎損傷分級Ⅰ級例數(shù)均顯著多于同組治療前,且觀察組顯著高于對照組同期,差異均有統(tǒng)計學(xué)意義(P0.05)。兩組患者隨訪率均為100%,不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:在常規(guī)治療的基礎(chǔ)上,地爾硫卓聯(lián)合環(huán)孢素治療腎病綜合征伴急性腎損傷的療效顯著,且安全性均較好。
[Abstract]:Objective: to observe the efficacy and safety of diltiazem combined with cyclosporine in the treatment of nephrotic syndrome with acute renal injury. Methods: 66 cases of nephrotic syndrome with acute renal injury were randomly divided into control group (30 cases) and observation group (36 cases). The patients in the control group were treated with routine therapy, and the patients in the observation group were treated with diltiazem hydrochloride tablets for 15 mg, and cyclosporine soft capsules for 1. 5 mg/ (kg d), twice a day. The course of treatment was 20 days in both groups. The clinical efficacy, serum creatinine, urine protein volume (KIM_ (-1), 24 h), 24 h urine volume, acute renal injury grade, follow-up and recurrence were observed before and after treatment, and adverse reactions were recorded. Results: the remission rate was significantly higher in the observation group than that in the control group, and the recurrence rate was significantly lower than that in the control group (P0.05). Before treatment, there was no significant difference in serum creatinine, KIM_ (-1), 24 h urine protein content, 24 h urine volume and acute renal injury grade between the two groups (P0.05). The levels of serum creatinine, KIM_ (-1), 24 h urine protein in the observation group were significantly lower than those in the same group after 2 weeks, 1 month and 1 month in the control group, and those in the observation group were significantly lower than those in the control group. 24 h urine volume, acute renal injury grade I cases were significantly higher than the same group before treatment, and the observation group was significantly higher than the control group in the same period, the difference was statistically significant (P0.05). The follow-up rate of the two groups was 100 and the incidence of adverse reactions was not statistically significant (P0.05). Conclusion: on the basis of routine therapy, diltiazem combined with cyclosporine is effective and safe in the treatment of nephrotic syndrome with acute renal injury.
【作者單位】： 海南省中醫(yī)院腎病風(fēng)濕科;
【分類號】：R692

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 楊煥芳;萬啟軍;何永成;;腎病綜合征伴發(fā)急性腎損傷的臨床及病理分析[J];廣東醫(yī)學(xué);2016年13期

2 寧文慧;韓子明;韓玫瑰;;環(huán)孢素A聯(lián)合激素治療兒童原發(fā)性腎病綜合征的單中心臨床療效觀察[J];中華臨床醫(yī)師雜志(電子版);2016年08期

3 李雨;郭慧蕾;張永;;腎病綜合征伴急性腎損傷患者地爾硫合并環(huán)孢素的超說明書用藥分析[J];中國醫(yī)院藥學(xué)雜志;2016年05期

4 安金龍;周麗娜;張文軍;金仲達(dá);俞仲賢;張雪峰;;中西醫(yī)結(jié)合治療難治性腎病綜合征28例臨床觀察[J];江蘇中醫(yī)藥;2015年10期

5 李U，

本文編號：2312493